Dr. Sara James
Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a global risk to public health. One of the first-line treatments for MRSA infections is still vancomycin. However, in recent years, isolates of S. aureus that are completely resistant to vancomycin have emerged.
Clinical isolates of both Staphylococcus aureus and coagulase-negative staphylococci have been found to be resistant to vancomycin. Given that vancomycin has long been the treatment of choice for gram-positive organisms that are resistant to antibiotics, the emergence of vancomycin resistance poses a serious threat to public health. Even though major efforts are being made to learn more about vancomycin resistance, a lot is still unknown at this time. The major epidemiologic, microbiological, and clinical features of vancomycin resistance in S. aureus and coagulase-negative staphylococci are discussed in this article. Definitions, laboratory detection of vancomycin resistance, and infection control concerns pertaining to vancomycin-resistant staphylococci are among the issues that are shared by coagulase-negative staphylococci and S. aureus. The epidemiology, risk factors for infection, mechanisms of resistance, and management options of each organism are then the focus of the remainder of the article.
KeywordsMicrobiological; Vancomycin-resistant Staphylococcus aureus; S. aureus; Vancomycin-resistant S. aureus; Glycopeptide antibiotic
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu